Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XELIRI-bevacizumab versus FOLFIRI-bevacizumab for first-line metastatic colorectal cancer
ACTRN12610000270011Phase 3Completed
- Sponsor
- HeCOG
- Start
- Sep 2006
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of irinotecan, capecitabine, bevacizumab, fluorouracil and folinic acid, sponsored by HeCOG. Started Sep 2006; status: completed.
02
Drugs
irinotecancapecitabinebevacizumabfluorouracilfolinic acid
Beyond the preview
Go deeper on ACTRN12610000270011.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12610000270011.